Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mycobacterium cell wall-DNA Complex - Liminal BioSciences

Next Previous
Drug Profile

Mycobacterium cell wall-DNA Complex - Liminal BioSciences

Alternative Names: EN3348; MCC; MCC/HA; MCNA; Mycobacterium Cell Wall-DNA Complex/hyaluronic acid; Mycobacterium phlei cell-wall - nucleic acid complex; Prostacidin; Urocidin

Latest Information Update: 26 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bioniche Life Sciences
  • Developer Endo Pharmaceuticals; Liminal BioSciences; Telesta Therapeutics
  • Class Antiandrogens; Antineoplastics; DNA
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Interleukin 12 stimulants; Interleukin 6 stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bladder cancer; Cancer; Infections; Peritoneal cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 26 Nov 2024 Discontinued - Phase-I for Prostate cancer in Canada (Intratumoural) (Liminal Biosciences pipeline, November 2024)
  • 26 Nov 2024 Discontinued - Phase-III for Bladder cancer (Second-line therapy or greater) in United Kingdom, Netherlands, Germany, Poland (Intravesicular) (Liminal Biosciences pipeline, November 2024)
  • 26 Nov 2024 Discontinued - Preclinical for Cancer in Canada (Parenteral) (Liminal Biosciences pipeline, November 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top